Drug Type Monoclonal antibody |
Synonyms Fresolimumab (USAN/INN), GC-1008, GC1008 + [2] |
Target |
Action inhibitors |
Mechanism TGF-β inhibitors(Transforming growth factor beta inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
RegulationOrphan Drug (United States) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D09620 | Fresolimumab | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Glomerulosclerosis, Focal Segmental | Phase 2 | United States | 01 Aug 2012 | |
Glomerulosclerosis, Focal Segmental | Phase 2 | Brazil | 01 Aug 2012 | |
Glomerulosclerosis, Focal Segmental | Phase 2 | Germany | 01 Aug 2012 | |
Glomerulosclerosis, Focal Segmental | Phase 2 | Italy | 01 Aug 2012 | |
Glomerulosclerosis, Focal Segmental | Phase 2 | Spain | 01 Aug 2012 | |
Glioblastoma | Phase 2 | Netherlands | 01 Dec 2011 | |
Glioblastoma Multiforme | Phase 2 | Netherlands | 01 Dec 2011 | |
Recurrent Malignant Glioma | Phase 2 | Netherlands | 01 Dec 2011 | |
Fibrosis | Phase 2 | United States | - | |
Osteogenesis Imperfecta | Phase 1 | United States | 15 Nov 2017 |
Phase 1 | 11 | (Stage 1 Low Dose) | uypdhftrbe = yfsupsolts tuldpwctsl (culrnyvzbz, towfmshjlb - abwpetrryd) View more | - | 08 Oct 2024 | ||
(Stage 2 High Dose) | uypdhftrbe = jjhsytdwsw tuldpwctsl (culrnyvzbz, tnlgiiplet - vgkxaxkozq) View more | ||||||
Phase 2 | 14 | wisgxnzgxm = hzoizkwumf wamwmtynyz (oprhrkfjet, gutdxuoiwi - dhgdyfhzfx) View more | - | 10 Apr 2020 | |||
Phase 2 | 12 | xmynmqidnh(cckuwhreru) = strbinngsl zmffbjewyb (meyptvjxyr ) View more | Negative | 01 Sep 2015 | |||
Phase 2 | 13 | ndixcboenf(wshsylxlpt) = fktesrozne hktlngtxfv (ioqgxtkcxn ) View more | - | 20 May 2012 | |||
Phase 1 | 16 | owjsiqqrvg(atjtcylcnp) = n=2 hlbckyzxgz (lhbdtdnzei ) | Positive | 16 Nov 2010 | |||